4 November 2025
Boehringer Ingelheim and CDR-Life Sign Licensing Deal for CDR111 in Autoimmune Diseases
The agreement expands a successful partnership, focusing on CDR111 to target B cells in autoimmune diseases, with potential payments up to USD 570 million.